BUZZ-Lumexa shares rise after Truist gives "Buy" rating
路透社2026/10/05 12:21On October 5th, shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading to $10.6. Brokerage Truist Securities initiated coverage with a “Buy” rating and a target price of $18, which implies about 74% upside from the previous trading day’s close. The company offers diagnostic imaging services, including MRI, CT, and PET scans, as well as X-ray, ultrasound, and mammography services. All five brokerages currently covering LMRI have assigned it a “Buy” or higher rating, with a median target price of $17.50, according to data compiled by LSEG. As of the previous close, LMRI’s share price has declined 44.22% year-to-date. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to the possibility of errors or missing context in automated translations, Reuters does not guarantee their accuracy and provides these translations solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
October 5 - ** Shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading, at $10.6.
** Brokerage Truist Securities initiated coverage (link), with a "Buy" rating and a target price of $18.
** This target price suggests an upside of about 74% compared to the previous trading day's closing price.
** The company offers diagnostic imaging services, including MRI, CT and PET scans, as well as X-ray, ultrasound and mammography services.
** All 5 brokerages currently covering this stock rate LMRI as "Buy" or above; their median target price is $17.50 — LSEG compiled data.
** As of the previous trading day’s close, LMRI shares had fallen 44.22% year-to-date.
(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stocks ignore high yield warnings! Tech stocks lead gains, pushing the S&P 500 near historic highs
As investors largely ignored concerns arising from bond yields reaching multi-decade highs, tech stocks led the rally, pushing the S&P 500 close to its historical high.
BUZZ - Australia's Stakk shares surge due to IBM software contract
On October 5th, Stakk (SKK.AX) shares rose as much as 26.1% to AUD 0.029, marking the largest intraday gain since September 29. The digital trust technology company announced that IBM will use its AI-driven document processing and verification software under a contract. The software will be deployed across Australia and New Zealand. The initial contract term is one year and will immediately generate revenue for the company. Including today's trading, the stock has declined 30.3% so far this year.
The Japanese Yen firms on a BoJ speech about AI and gives it all back
OpenAI reportedly in talks with UAE capital for $30 billions financing; multiple funds may form a consortium to invest up to $10 billions
According to sources familiar with the matter, OpenAI is in funding talks with several UAE investment funds, including Abu Dhabi’s MGX, in hopes that they will become key investors in a new funding round of at least $30 billions.
Crypto prices
More
